Microbix Biosystems Inc T.MBX

New Press Release - Microbix Reports Record Results for Q1 Fiscal 2024

Record Revenues of $8.4 million and Record Net Income of $2.5 million MISSISSAUGA, Ontario, Feb. 14, 2024 (GLOBE NEWSWIRE) -- Microbix Biosystems Inc. (TSX: MBX, OTCQX: MBXBF, Microbix®), a life sciences innovator, manufacturer, and exporter, reports results for its first quarter of fiscal 2024...read article.

[lscfa]

The bozos should have disclosed how much was the one-time consulting fee expense for Kinlytic so that people backing out the one-time Kinlytic revenues could get a true net income....     With Kinlytic Without Kinlytic Revenue 8,407,884 4,201,912

[lscfa]

  Qtr ending  G&A expense Dec 23 2,804,716 Sep 23 1,485,588 Jun 23 2,104,025 Mar 23 1,502,037 Dec 22 1,601,099 Sep

[lscfa]

Mgmt need to get base business growing...   Qtr ending  Antigen QAP DxTM Royalties/Licensing Total Revenue Dec 23 1,953,677 2,248,236 0 4,205,972 8,407,885

[wizzdumb]

You should really listen to the call. Will be record year w/o the Kinlytic royalties was clearly stated, aka core business. 

[prophetoffactz]

They expect record revenue ignoring Kinlytic. Given record revenue is  $19.1 and revenue in Q1 was $4.2 million(minus Kinlytic) the next three quarter have to average in excess of approximately $5 million per quarter.

[ssdasmm]

That's what they are gearing up for. If you both don't believe or the one of you with 2 aliases don't believe then why are you still in the stock?

[lscfa]

Co. needs to do $30 million/yr revenue to justify current share price    Revenue 30,000,000 50% gross margin 15,000,000 Cash Overhead -10,000,000 ebitda 5,000,000 Diluted shs 181

[ssdasmm]

lol

[wizzdumb]

Now model $50M earnings in 2027 which it totally achievable on Kinlytic alone, with one indication, in US and Europe. 

[prophetoffactz]

Iscfa, "Minute 64 webinar CFO thinks 2024 revenues could be $26 million" That's about $6 million per quarter, on average, for the next three quarters. 

[prophetoffactz]

I think they want to sell their options into this...

[lscfa]

Mentioned in webinar $500,000 US fee paid to Kinlytic consultant in G&A costs.

[ssdasmm]

Small price to pay for a multi million dollar revenue stream.  Small price to pay if Sequel decides to take them over before paying royalties.  

[lscfa]

Minute 64 webinar CFO thinks 2024 revenues could be $26 million

[Mbxwatcher]

That would seem to make sense....... 11 antigens 10 QAPS  4.2 Kinlytic .5  Royalties 25.7 Seems to be reasonable that is pretty close to the run rate they are at now..... with Kinlytic coming down the pipe, and QAPS growing, I think its fair to say our prospects for growth are good.    One comment that was made is the their costs are scaled up for larger revenues, so EBITDA

[lscfa]

If you exclude the Kinlytic and DTM revenues (Mar21 to June22) this co. makes little profit. Mgmt needs to get on with it.     Qtr ending  Revenue Net income Dec 23 8,407,884 2,455,379 Sep 23 4,263,655

[wizzdumb]

They addressed that also, significant investments have been made and continue to provide for capability to meet stated revenue goal of $50M.  The entire Kinlytic business plan is for royalties and milestone payments, which will potential eclipse core business.    Watch the webinar.